KalVista Pharmaceuticals, Inc.KALVNASDAQ
Loading
PB Ratio: Premium ValuationElevated
Percentile Rank100
3Y CAGR+62.1%
5Y CAGR+25.4%
Year-over-Year Change
Price-to-book ratio
3Y CAGR
+62.1%/yr
vs -17.6%/yr prior
5Y CAGR
+25.4%/yr
Recent acceleration
Acceleration
+79.6pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
3.1x
Strong expansion
Streak
2 yr
Consecutive growthElevated
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 7.17 | +254.6% |
| 2024 | 2.02 | +31.6% |
| 2023 | 1.54 | -8.7% |
| 2022 | 1.68 | -9.2% |
| 2021 | 1.85 | -19.8% |
| 2020 | 2.31 | -35.5% |
| 2019 | 3.59 | -1.6% |
| 2018 | 3.64 | +62.1% |
| 2017 | 2.25 | -1.2% |
| 2016 | 2.27 | - |